* Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication.
** Arranged by type of listing and date of announcement.
*** Potential means Intention to Float (ITF) or similar announcement has been made.
**** A corporate client of Hybridan LLP.
None
None
The West African focused gold Company announced the latest assay results from the ongoing 2026 drill programme being conducted at its flagship Sanankoro Gold Project in southern Mali. The latest assay results have been received from the Dakounkoura South target, a greenfield target located along the northern end of the Sanankoro structure, 1km directly north of the Zone B North deposit. This drilling tested an area which has had very limited previous drilling, and successfully identified 500 metres of strike of a new and promising zone of oxide mineralisation within a 2km radius of the planned process plant. The 2026 drill programme aims to unlock the broader long-term potential of Sanankoro by testing both extensions to existing deposits and a number of highly prospective near-mine greenfield targets in order to expand the current JORC compliant MRE of 1,044koz at 1.04 g/t gold and extend the Reserve mine life beyond the 10.2 years outlined in the 2025 definitive feasibility study.
The mining Company established to acquire mining opportunities in the critical and strategic metals sector announced the completion of 3D block modelling and confirmation of copper oxide mineralisation at the Molulu Copper/Cobalt Project in the Democratic Republic of Congo. The Company also announced that it is collaborating with a potential offtake partner to test a total of circa 300 kilograms of ore from existing stockpiles and evaluate sample recovery within the following Total Copper ranges: 1%-1.5%, 1.5%-2%, and >2%.
The Australian-focused critical and precious minerals explorer announced encouraging gold assays at shallow depth from multiple neighbouring drill holes at central Curley’s prospect within its Peak Hill project in Western Australia, where 30 holes totalling 1,406m were completed. As a result, Forgent will initiate immediate development drilling at Central Curleys. The gold assays from 5 metres downhole across multiple neighbouring holes strengthen the central Curley’s exploration opportunity, led by primary one-metre gold assays of up to 4.32g/t in CAC010 and 4.10g/t in CAC003, with 3.71g/t, 1.88g/t and 1.49g/t in other neighbouring holes. The strong grades are complemented by multi-metre gold bearing intervals including two seven metre gold bearing intervals from two drill holes of 7m averaging 2.32g/t gold from 26m in CAC010, including 1m at 4.32g/t from 28m, and 7m averaging 1.05g/t from 49m at CAC011 including 1m at 3.63g/t from 50m. The rig returns to site in the coming days to drill approximately 51 development holes at central Curley’s on 20x20m, 40x40m and 80x80m grids and an additional four deeper holes in Northern Curleys, after which drilling at Cathedral will likely continue.
The mineral resources and hydrocarbon exploration Company completed recent exploration activities at its Juno Gold Project in Western Australia, including a native title heritage survey, field reconnaissance and ground truthing of priority magnetic targets. The Company has also engaged Dr Finbarr Murphy to undertake a litho-structural geological interpretation and targeting exercise to guide the next phase of drill targeting.
The global detection Company delivering best-in-class solutions for the advanced imaging and CBRN (Chemical, Biological, Radiological, and Nuclear) detection markets announced that it has received a follow-on $1.4m order from an existing OEM customer in the Advanced Imaging division. The order is for the supply of CZT-based detector components for the customer’s medical systems. The Group will commence delivery immediately, which is expected to be completed over the next 12 months.
The diversified financial services group serving the Isle of Man and the UK provided an operational update for the quarter ended 30 September. The Group's progress is being principally driven by three complementary business areas: Conister Bank Limited's disciplined deployment of liquidity and continued operational improvement, Payment Assist Limited's expansion in line with the Group's medium-term strategy, and the development and potential monetisation of investments held through Manx Ventures Limited. Conister Bank delivered a strong Q3, with net interest income increasing by 9.6% to £10.3m with a total capital ratio of 16.1%. The new £40m Stafferton structured finance facility bolsters structured finance business, which now has over £313m of documented facilities in the market.
The 3D Genomics Company has entered into its first commercial agreement with a major pharmaceutical company for the use of EpiSwitch® Orion, its cloud-based 3D genomics platform, as part of a biomarker discovery programme in inflammatory bowel disease. The agreement is with Johnson & Johnson and follows OBD's first commercial Orion agreement, with the University of Oxford-led OPTIMISE psoriatic arthritis programme, announced on 28 July.
The cybersecurity, advisory and managed security services Group announced that Brookcourt Solutions Limited has secured a strategic three-year contract with a major UK telecommunications provider, with a total value of approximately £9.2m. The agreement represents a three-year expansion of Brookcourt's existing relationship with the UK telecoms provider and combines the extension of existing cybersecurity services, increased deployment across the customer's estate and the award of a new cloud security requirement following the displacement of an incumbent provider.
The clinical-stage biotechnology Company developing psychedelic therapeutics for addiction, post-traumatic stress disorder and depression announced that the US Patent and Trademark Office has allowed its method-of-use patent application covering the treatment of all behavioural addictions with ketamine at dissociative doses of at least 50 mg. The allowance marks a major milestone for Solvonis, providing a broad US patent position across behavioural addictions, with substantial patient populations, significant unmet medical need and scope for multiple potential partnerships and licensing deals. Binge eating and gambling disorders are the first commercial priorities, representing large, underserved markets with limited or no approved medicines. The breadth of the claims provides a foundation for building a substantial behavioural-addiction business alongside Solvonis’ Phase 3 alcohol programme and NIDA-funded work on cocaine and methamphetamine addiction, expanding the Company’s commercial potential.
The provider of audit and assurance services and the holding company for TIAA Limited updated on trading ahead of the publication of its interim results for the six months ended 30 September, which are expected to be announced in December 2026. The Board now expects revenue for the period to be approximately 17% lower compared with the corresponding period in the prior year, which is expected to lead to a loss being reported for the first half of the financial year. Trading has been adversely affected following the introduction of a new tool for resource allocation which has taken longer to implement than expected and the results of the first half of the financial year are expected to impact the financial performance for the full year.
13 October: Voltage X, the AI-native creative and communications Company announced its intention to IPO onto AIM. Founded in 2021 and headquartered in Melbourne, Australia, the Group provides public relations, digital marketing, content creation, marketing analytics and influencer management services to an international client base, with a primary focus on the real estate, hospitality, sports and retail sectors. The Company intends to raise gross proceeds of US$3-4m by way of a placing. Anticipated market capitalisation on admission is TBC and expected Admission date is mid-November 2026.
5 October: Liberty Minerals announced its intention to IPO onto AIM. The mineral exploration Company is focused on tungsten and associated minerals including antimony, molybdenum, copper, silver and zinc in Arizona and Idaho. On Admission to AIM, it will own the Boriana and Buckhorn projects, comprising unpatented mining claims on US Bureau of Land Management land. Boriana, historically one of Arizona’s principal tungsten producers, is the Company’s primary exploration focus, with Buckhorn a longer-term target. Liberty Minerals raised £662,000 through a pre-IPO fundraise in June 2026 and intends to raise further funds through a placing to finance exploration and development. Deal details remain TBC and first day of dealings expected mid-November 2026.
3 November: Atomic Metals announced its attention to IPO onto AQSE. The project acquisition, exploration and development vehicle seeking strategic commodity projects, is focused on critical and precious metals including but not limited to Copper, Silver, Uranium and Gold exploration opportunities, in mining positive jurisdictions. The Company plans to deploy extensive exploration programmes generating impactful news streams for investors. The countries of operation will likely include the USA, Canada and/or Australia but Atomic Metals will pursue what the Directors believe to be the best exploration opportunities feasible, but primarily focused in Tier 1 mining jurisdictions. The fundraise will be split into 2 tranches, a c.£720k pre-IPO Fundraising prior to Admission completed at 2.25p, and an additional circa (£1.3m to £1.5m) IPO Fundraise conditional on Admission at 3p per share. The expected admission date is 12 November 2026.
22 October: IntelliAM AI (AQSE:INT) The provider of AI-driven software solutions for the manufacturing and engineering sectors announced its attention to move to AIM from AQSE. It has conditionally raised approximately £6.3m (before expenses) through a placing of 8,919,598 new Ordinary Shares at 70p per Ordinary Share, and the conditional conversion of unsecured convertible loan notes with an aggregate principal value and accrued interest of £31,282 into 44,688 new Ordinary Shares pursuant to their existing terms, as set out in the Company’s announcement made on 7 July 2026. Admission is expected to become effective, and dealings in the Enlarged Issued Share Capital are expected to commence at 8.00 a.m. on 20 November 2026.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
